Vis enkel innførsel

Health technology assessment of four drugs for patients with metastatic castration resistant prostate cancer

dc.contributor.authorSæterdal, Ingvil von Mehren
dc.contributor.authorDesser, Arna S.
dc.contributor.authorPike, Eva Flovild
dc.contributor.authorHamidi Ashtiani, Vida
dc.contributor.authorHarboe, Ingrid
dc.contributor.authorOdgaard-Jensen, Jan
dc.contributor.authorKlemp, Marianne
dc.date.accessioned2022-04-13T06:05:13Z
dc.date.available2022-04-13T06:05:13Z
dc.date.created2022-04-11T07:55:10Z
dc.date.issued2016
dc.identifier.isbn978-82-8082-760-9
dc.identifier.urihttps://hdl.handle.net/11250/2991134
dc.language.isoeng
dc.publisherNorwegian Institute of Public Health
dc.relation.urihttps://nyemetoder.no/Documents/Rapporter/Rapport_2016_prostatakreft_medisiner.pdf
dc.titleHealth technology assessment of four drugs for patients with metastatic castration resistant prostate cancer
dc.title.alternativeHealth technology assessment of four drugs for patients with metastatic castration resistant prostate cancer
dc.title.alternativeMetodevurdering for fire legemidler for pasienter med metastaserende kastrasjonsresistent prostatakreft
dc.typeResearch report
dc.description.versionpublishedVersion
dc.source.pagenumber78
dc.identifier.cristin2016574
cristin.ispublishedtrue
cristin.fulltextoriginal


Tilhørende fil(er)

Thumbnail
Filnavn:
Seterdal-2016-Hea.pdf
Størrelse:
1018.Kb
Format:
PDF
Åpne

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel